ArticleTranslational vision science & technology2025
Effects of Benzalkonium Chloride, a Preservative in Topical Drugs, on the Barrier Function of Human Corneal Epithelial Cells.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation.International ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: To assess the influence of varying concentrations of benzalkonium chloride (BAK), the predominant preservative utilized in ophthalmic formulations, on the barrier integrity and mitochondrial function of primary cultured human corneal epithelial cells (HCECs). Methods: Primary HCEC monolayers were exposed to BAK at concentrations ranging from 0.02% to 0.00002%. The barrier function was monitored using electric cell-substrate impedance sensing (ECIS), where a decrease in electrical resistance signified a loss of barrier function. Mitochondrial function was evaluated after 24 hours of BAK exposure with the Seahorse XFe96 Flux Analyzer, which measured basal respiration, adenosine triphosphate (ATP) production, and maximal respiration. Results: High BAK concentrations (≥0.02%) caused a rapid, dose-dependent decrease in resistance, exceeding 40% within 1 hour. In contrast, lower concentrations (0.00025%-0.002%) led to a delayed, gradual reduction. Specifically, 0.00025% BAK resulted in a 37% decrease in resistance by 72 hours, whereas 0.0001% caused a 26% reduction; concentrations ≤ 0.00005% had no significant effect. Increased capacitance accompanied the resistance loss, indicating membrane disturbance. Seahorse analysis revealed that BAK concentrations ≥ 0.00005% significantly reduced basal respiration and ATP production. Maximal respiration decreased at higher doses (≥0.0001%). Conclusions: BAK induces concentration-dependent, cumulative toxicity in HCECs, causing rapid membrane disruption and irreversible barrier failure at or above its critical micelle concentration (CMC), along with ongoing sub-CMC toxicity through mitochondrial suppression at lower doses. These findings highlight the need for preservative strategies that reduce both acute and chronic epithelial damage in ophthalmic applications. Translational Relevance: Real-time impedance and mitochondrial assessments determine thresholds for BAK toxicity, guiding the development of safer ophthalmic formulations to protect the ocular surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.